Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial

BACKGROUND: Alzheimer's disease (AD) is characterized by early and region-specific declines in cerebral glucose metabolism. Ketone bodies are produced by the body during glucose deprivation and are metabolized by the brain. An oral ketogenic compound, AC-1202, was tested in subjects with probab...

Descripción completa

Detalles Bibliográficos
Autores principales: Henderson, Samuel T, Vogel, Janet L, Barr, Linda J, Garvin, Fiona, Jones, Julie J, Costantini, Lauren C
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2731764/
https://www.ncbi.nlm.nih.gov/pubmed/19664276
http://dx.doi.org/10.1186/1743-7075-6-31

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2731764/
https://www.ncbi.nlm.nih.gov/pubmed/19664276
http://dx.doi.org/10.1186/1743-7075-6-31

Ejemplares similares